TrialThe Lancet. Oncology2014

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Eugene D Kwon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.